Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137637

Published: 2020

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137709

Published: 2020

Journal Articles

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Jagan R. Muppidi, MD PhD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Lydia L. Chou, CRNP, Sarah Evans, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134115

Published: 2020

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Michail S. Lionakis, MD ScD, Christopher Melani, MD, John A. Butman, MD PhD, Stefania Pittaluga, MD PhD, A. Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, Richard F. Little, MD MPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2018-99-112184

Published: 2018

Journal Articles

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Christopher Melani, MD, Mark Roschewski, MD, Stefania Pittaluga, MD PhD, Jeffrey Cohen, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 785.

https://doi.org/10.1182/blood-2018-99-116707

Published: 2018

Journal Articles

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Nakhle S. Saba, MD, A. Nicole Lucas, RN, Allison Jacob, MS, Erik Yusko, PhD, Seth M. Steinberg, PhD, Elaine S. Jaffe, Adrian Wiestner, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2018) 132 (Supplement 1): 147.

https://doi.org/10.1182/blood-2018-99-112573

Published: 2018

Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood (2017) 130 (Supplement 1): 188.

https://doi.org/10.1182/blood.V130.Suppl_1.188.188

Published: 2017

Journal Articles

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

Christopher Melani, MD, Stefania Pittaluga, MD PhD, Lydia Yee, CRNP, Andrea Lucas, RN, Margaret Shovlin, RN, Allison Jacob, MS, Kenneth Chan, PhD, Marissa Vignali, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2017) 130 (Supplement 1): 2728.

https://doi.org/10.1182/blood.V130.Suppl_1.2728.2728

Published: 2017

Journal Articles

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Christopher Melani, MD, Ranjana H. Advani, MD, Mark Roschewski, MD, Kelsey M. Walters, BS, Clara C. Chen, MD, Lucia Barrato, MD, Mark A. Ahlman, MD, Milos D. Miljkovic, MD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2017) 130 (Supplement 1): 2859.

https://doi.org/10.1182/blood.V130.Suppl_1.2859.2859

Published: 2017

NARROW

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only